Mandate

Vinge advises KKR on its significant investment in Söderberg & Partners

February 08, 2019 M&A

Vinge has advised the global investment firm KKR in connection with KKR entering into an agreement with Söderberg & Partners, TA Associates and certain other selling shareholders to acquire a substantial minority shareholding in Söderberg & Partners.

The transaction is subject to customary conditions precedent including regulatory approvals, and is expected to be completed during the second quarter of 2019. 

Söderberg & Partners is a leading non-bank provider of wealth management and corporate pension and insurance services in the Nordic region and the Netherlands. KKR will continue to support and assist Söderberg & Partners on its strategy of rolling out its successful platform across the Nordic region and internationally, developing its product portfolio and services proposition, and enhancing its capabilities across investment management and research.

Vinge’s team consisted of, among others, Christina Kokko, Johan Larsson, Samra Baytar, Desirée Sjöblom, Elsie Nassar and Hanna Risberg (Corporate and M&A), Emma Stuart-Beck, Caroline Krassén, Malin Haag, Henrik Schön, Mikaela Lang and Julia Hirschberg (Regulatory and Financial Services) Viveka Classon, Paulina Malmberg (Insurance), Isabell Nielsen (Commercial Agreements), Lisa Ullman (Employment), Nicklas Thorgerzon (IT), Vilhelm Rondahl and Josefine Lanker (Banking and Financing), Agnes Perbo and Karolina Cohrs (Real Estate/Lease Agreements), Sofia Bergenstråhle (IP) and Viktoria Owetz (VDR assistant).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026